27897214|t|LINC00978 predicts poor prognosis in breast cancer patients
27897214|a|Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death among women worldwide. Long non-coding RNAs (lncRNAs) are a class of non-coding RNAs in the human genome that involves in breast cancer development and progression. Here, we identify a lncRNA, LINC00978, which is upregulated in breast cancer cell lines and tissues compared with corresponding controls. Furthermore, LINC00978 expression is negatively associated with hormone receptor (HR) status in 195 breast cancer patients studied (p = 0.033). Kaplan-Meier survival analysis shows that patients with high LINC00978 expression have poorer disease-free survival (DFS) than those with low LINC00978 expression (p = 0.012), and multivariate analysis identifies LINC00978 as an independent prognostic factor in breast cancer (p = 0.008, hazard ratio [HR] = 2.270, 95% confidence interval [CI] 1.237-4.165). Our study indicates that LINC00978 may be an oncogene in breast cancer, and can serve as a potential biomarker to predict prognosis in breast cancer patients.
27897214	0	9	LINC00978	T028	C3810893
27897214	19	33	poor prognosis	T033	C0278252
27897214	37	50	breast cancer	T191	C0678222
27897214	51	59	patients	T101	C0030705
27897214	60	73	Breast cancer	T191	C0678222
27897214	97	106	diagnosed	T033	C0011900
27897214	107	113	cancer	T191	C0006826
27897214	130	135	cause	T169	C0015127
27897214	139	145	cancer	T191	C0006826
27897214	146	151	death	T040	C0011065
27897214	158	163	women	T098	C0043210
27897214	175	195	Long non-coding RNAs	T114,T123	C3494264
27897214	197	204	lncRNAs	T114,T123	C3494264
27897214	221	236	non-coding RNAs	T114	C0887909
27897214	244	256	human genome	T028	C0017429
27897214	274	287	breast cancer	T191	C0678222
27897214	288	299	development	T169	C1527148
27897214	304	315	progression	T046	C0242656
27897214	337	343	lncRNA	T114,T123	C3494264
27897214	345	354	LINC00978	T028	C3810893
27897214	380	393	breast cancer	T191	C0678222
27897214	394	404	cell lines	T025	C0007600
27897214	409	416	tissues	T024	C0040300
27897214	417	425	compared	T052	C1707455
27897214	445	453	controls	T096	C0009932
27897214	468	477	LINC00978	T028	C3810893
27897214	478	488	expression	T045	C0017262
27897214	492	502	negatively	T033	C1513916
27897214	503	518	associated with	T080	C0332281
27897214	519	535	hormone receptor	T116,T192	C0019929
27897214	537	539	HR	T116,T192	C0019929
27897214	541	547	status	T080	C0449438
27897214	555	568	breast cancer	T191	C0678222
27897214	569	577	patients	T101	C0030705
27897214	599	629	Kaplan-Meier survival analysis	T081	C1720943
27897214	641	649	patients	T101	C0030705
27897214	660	669	LINC00978	T028	C3810893
27897214	670	680	expression	T045	C0017262
27897214	686	692	poorer	T080	C2700379
27897214	693	714	disease-free survival	T081	C0242793
27897214	716	719	DFS	T081	C0242793
27897214	741	750	LINC00978	T028	C3810893
27897214	751	761	expression	T045	C0017262
27897214	779	800	multivariate analysis	T081	C0026777
27897214	812	821	LINC00978	T028	C3810893
27897214	840	857	prognostic factor	T201	C1514474
27897214	861	874	breast cancer	T191	C0678222
27897214	887	899	hazard ratio	T081	C2985465
27897214	900	903	[HR	T081	C2985465
27897214	918	937	confidence interval	T081	C0009667
27897214	939	941	CI	T081	C0009667
27897214	982	991	LINC00978	T028	C3810893
27897214	1002	1010	oncogene	T028	C0029016
27897214	1014	1027	breast cancer	T191	C0678222
27897214	1058	1067	biomarker	T201	C0005516
27897214	1079	1088	prognosis	T058	C0033325
27897214	1092	1105	breast cancer	T191	C0678222
27897214	1106	1114	patients	T101	C0030705